Volume 22 Issue 8
Aug.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(8): 1325-1327
WU Mengqi, SHI Peng, LI Qianqian, TIAN Jialing, LI Qiang. Correlation between peripheral inflammatory cytokines IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease[J]. Chinese Journal of General Practice, 2024, 22(8): 1325-1327. doi: 10.16766/j.cnki.issn.1674-4152.003627
Citation: WU Mengqi, SHI Peng, LI Qianqian, TIAN Jialing, LI Qiang. Correlation between peripheral inflammatory cytokines IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease[J]. Chinese Journal of General Practice, 2024, 22(8): 1325-1327. doi: 10.16766/j.cnki.issn.1674-4152.003627
shu

Correlation between peripheral inflammatory cytokines IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease

doi: 10.16766/j.cnki.issn.1674-4152.003627

  • Department of Neurology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 202304295107020075

 2021byzd049

 Byycx22119

  • Received Date: 2023-11-01
    Available Online: 2024-11-19
    Abstract
  •   Objective  To analyze the correlation between the levels of IL-10 and IL-32 and the cognitive dysfunction and non-motor symptoms of Parkinson' s disease (PD), we measured levels of IL-10 and IL-32 in the peripheral blood of Parkinson' s disease patients and healthy controls and evaluated their cognitive function and non-motor symptoms.  Methods  Sixty patients with Parkinson' s disease in the First Affiliated Hospital of Bengbu Medical University from January 2022 to October 2023 were selected as the observation group, and 60 healthy subjects were selected as the control group. Serum concentrations of IL-10 and IL-32 in the two groups were detected by ELISA. The cognitive function and non-motor symptoms of the two groups were evaluated using the simple mental state checklist and the motor symptom assessment scale. The correlation between peripheral inflammatory factors IL-10 and IL-32 and cognitive dysfunction and non-motor symptoms of Parkinson' s disease was analyzed by hierarchical correlation method.  Results  The level of IL-10 in the peripheral blood of PD group was [136.60 (117.05, 169.70) pg/mL], which was higher than that of the control group [110.90 (92.15, 129.50) pg/mL, P < 0.01]. The level of IL-32 in the PD group was [32.35 (28.83, 37.68) pg/mL], which was higher than that in the control group [21.80 (20.60, 23.35) pg/mL, P < 0.01]. The level of IL-10 in the peripheral blood of PD patients was positively correlated with MMSE score (20.68±6.33) and NMSS score (103.17±11.25, P < 0.01). The level of IL-32 in the peripheral blood in PD patients was also positively correlated with MMSE score and NMSS score (P < 0.01).  Conclusion  The levels of inflammatory factors IL-10 and IL-32 in the peripheral blood of PD patients were higher than those of healthy controls, and were closely correlated with cognitive dysfunction and non-motor symptoms of PD.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    ZHENG Z, ZHANG S, ZHANG H, et al. Mechanisms of autoimmune cell in DA neuron apoptosis of Parkinson' s disease: recent advancement[J]. Oxid Med Cell Longev, 2022, 2022: 7965433. DOI: 10.1155/2022/7965433.
    [2]
    SEVERIANO E SOUSA C, ALARCÀO J, PAVÀO MARTINS I, et al. Frequency of dementia in Parkinson' s disease: a systematic review and meta-analysis[J]. J Neurol Sci, 2022, 432: 120077. DOI: 10.1016/j.jns.2021.120077.
    [3]
    GOLDMAN J G, SIEG E. Cognitive impairment and dementia in Parkinson disease[J]. Clin Geriatr Med, 2020, 36(2): 365-377. doi: 10.1016/j.cger.2020.01.001
    [4]
    KOULI A, CAMACHO M, ALLINSON K, et al. Neuroinflammation and protein pathology in Parkinson' s disease dementia[J]. Acta Neuropathol Commun, 2020, 8(1): 211. doi: 10.1186/s40478-020-01083-5
    [5]
    JURCAU A, ANDRONIE-CIOARA F L, NISTOR-CSEPPENTO D C, et al. The involvement of neuroinflammation in the onset and progression of Parkinson' s disease[J]. Int J Mol Sci, 2023, 24(19): 14582. DOI: 10.3390/ijms241914582.
    [6]
    WILLIAMS G P, SCHONHOFF A M, JURKUVENAITE A, et al. Targeting of the class Ⅱ transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson' s disease[J]. J Neuroinflammation, 2018, 15(1): 244. doi: 10.1186/s12974-018-1286-2
    [7]
    WANG J, LAI S, ZHOU T, et al. Progranulin from different gliocytes in the nucleus accumbens exerts distinct roles in FTD and neuroinflammation-induced depression-like behaviors[J]. J Neuroinflammation, 2022, 19(1): 318. doi: 10.1186/s12974-022-02684-8
    [8]
    DE ALBUQUERQUE R, KOMSI E, STARSKAIA I, et al. The role of interleukin-32 in autoimmunity[J]. Scand J Immunol, 2021, 93(2): e13012. DOI: 10.1111/sji.13012.
    [9]
    刘军. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002

    LIU J. Diagnostic criteria for Parkinson' s disease in China (2016 edition)[J]. Chinese Journal of Neurology, 2016, 49(4): 268-271. doi: 10.3760/cma.j.issn.1006-7876.2016.04.002
    [10]
    LIU X, LE W. Profiling non-motor symptoms in monogenic Parkinson' s disease[J]. Front Aging Neurosci, 2020, 12: 591183. DOI: 10.3389/fnagi.2020.591183.
    [11]
    MADABUSHI J S, GUPTA M, PEARCE B, et al. Parkinson' s disease: diagnostic challenges amidst transdiagnostic and overlapping mental health symptoms[J]. Cureus, 2023, 15(3): e36661. DOI: 10.7759/cureus.36661.
    [12]
    王伟, 曹庆华, 孙光玲, 等. 脑白质病变与帕金森病患者运动症状及非运动症状的相关性分析[J]. 中华全科医学, 2022, 20(2): 237-239. doi: 10.16766/j.cnki.issn.1674-4152.002321

    WANG W, CAO Q H, SUN G L, et al. Correlation analysis of white matter lesions and motor symptoms and non-motor symptoms in Parkinson' s patients[J]. Chinese Journal of General Practice, 2022, 20(2): 237-239. doi: 10.16766/j.cnki.issn.1674-4152.002321
    [13]
    CHEN X, HU Y, CAO Z, et al. Cerebrospinal fluid inflam-matory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis[J]. Front Immunol (2018)9: 2122. DOI: 10.3389/fimmu.2018.02122.
    [14]
    LIU H J, LI X Y, CHEN H, et al. Identification of susceptibility loci for cognitive impairment in a cohort of Han Chinese patients with Parkinson' s disease[J]. Neurosci Lett, 2020, 730: 135034. DOI: 10.1016/j.neulet.2020.135034.
    [15]
    SHU L, LIANG D, PAN H, et al. Gastrointestinal dysfunctions are associated with IL-10 variants in Parkinson' s disease[J]. Parkinsons Dis, 2018, 2018: 5908359. DOI: 10.1155/2018/5908359.
    [16]
    WANG B, CHEN T, WANG J, et al. Methamphetamine modulates the production of interleukin-6 and tumor necrosis factor-alpha via the cAMP/PKA/CREB signaling pathway in lipopolysaccharide-activated microglia[J]. Int Immunopharmacol, 2018, 56: 168-178. doi: 10.1016/j.intimp.2018.01.024
    [17]
    WANG M, PAN W, XU Y, et al. Microglia-mediated neuroinflammation: a potential target for the treatment of cardiovascular diseases[J]. J Inflamm Res, 2022, 15: 3083-3094. doi: 10.2147/JIR.S350109
    [18]
    ZHU H, HU S, LI Y, et al. Interleukins and ischemic stroke[J]. Front Immunol, 2022, 13: 828447. DOI: 10.3389/fimmu.2022.828447.
    [19]
    GAUTAM A, PANDIT B. IL32: The multifaceted and unconventional cytokine[J]. Hum Immunol, 2021, 82(9): 659-667. doi: 10.1016/j.humimm.2021.05.002
    [20]
    JSRIVASTAVA S, RASOOL M. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis[J]. Life Sci, 2022, 298: 120516. DOI: 10.1016/j.lfs.2022.120516.
    [21]
    DE ALBUQUERQUE R, KOMSI E, STARSKAIA I, et al. The role of Interleukin-32 in autoimmunity[J]. Scand J Immunol, 2021, 93(2): e13012. DOI: 10.1111/sji.13012.
    [22]
    KWON O C, PARK M C, KIM Y G. Interleukin-32 as a biomarker in rheumatic diseases: a narrative review[J]. Front Immunol, 2023, 14: 1140373. DOI: 10.3389/fimmu.2023.1140373.
    [23]
    TIAN Z J, SHEN Y, LI X R, et al. Increased interleukin-32, interleukin-1, and interferon-γ levels in serum from hepatitis B patients and in HBV-stimulated peripheral blood mononuclear cells from healthy volunteers[J]. J Infect Public Health, 2019, 12(1): 7-12. doi: 10.1016/j.jiph.2018.06.006
    [24]
    DU J, SHAO M M, YI F S, et al. Interleukin 32 as a potential marker for diagnosis of tuberculous pleural effusion[J]. Microbiol Spectr, 2022, 10(4): e0255321. DOI: 10.1128/spectrum.0255321.
    [25]
    ADAWY A, LI L, HIRAO H, et al. Potential involvement of IL-32 in cell-to-cell communication between macrophages and hepatoblastoma[J]. Pediatr Surg Int, 2023, 39(1): 275. doi: 10.1007/s00383-023-05557-0
    [26]
    LIU C, XU X, HUANG C, et al. Inhibition of IL-32 expression ameliorates cerebral ischemia-reperfusion injury via the NOD/MAPK/NF-κB signaling pathway[J]. J Mol Neurosci, 2020, 70(11): 1713-1727. doi: 10.1007/s12031-020-01557-0
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return